

November 7, 2007



Oxis International Biomarker Shown Effective in Assessing Antioxidant Potential of Dietary Supplements

FOSTER CITY, Calif.--

Oxis International Inc. (OTCBB:OXIS), a biopharmaceutical company focused on commercializing predictive biomarkers, clinical assays and nutraceutical and therapeutic products, announced today that CEO, Marvin S. Hausman MD., will present a poster entitled: "A Novel Method To Assess In-Vivo The Antioxidant Potential of Dietary Supplements and Foods" at the Supply Side West meeting in Las Vegas, Nevada, November 6-8, 2007.

This study describes the application of an antioxidant biomarker to measure the ability of whole food nutritional supplementation to increase the antioxidative/anti-inflammatory activity of mammalian blood. A human proof of principle clinical study revealed that the Oxis International Acute Oxidative Potential (Bioxytech AOP-490(TM)) assay could quantify antioxidant capacity within blood. The Mushroom Matrix(TM), a whole natural organic blend of powders that contain potent bioactive components, was studied in humans and horses and was shown to actively increase antioxidative/anti-inflammatory activity. Mushroom Matrix(TM) is produced by Golden Gourmet Mushrooms of San Marcos, CA.

"These studies represent an exciting first step in showing the ability of one of OXIS' antioxidant biomarkers to assess an individuals' inflammatory status and monitor attempts at nutritional supplementation," stated Marvin S. Hausman MD, CEO, Oxis International Inc. "Nutritional supplements, such as the Mushroom Matrix(TM), have the potential to correct cellular imbalance and control reactive oxygen species (ROS) associated with chronic inflammation and certain diseases such as cancer, bacterial infections, gastrointestinal disorders such as Crohn's disease, Alzheimer's Disease, heart disease and even aging. These studies suggest that proper nutritional supplementation may decrease the incidence and/or severity of these diseases."

Supply Side West is the world's largest event for healthy and innovative ingredients with 1,000+ booths. This three-day event offers food R&D and corporate management, dietary supplement executives and cosmeceuticals decision-makers the resources to develop new healthy products, learn about the latest developments in healthful ingredient applications

and examine thousands of innovative ingredients.

About OXIS and BioCheck:

Oxis International, Inc. develops technologies and products to research, diagnose, treat and prevent diseases of oxidative stress associated with damage from free radical and reactive oxygen species and the related increased inflammation that accompanies oxidative stress. OXIS presently holds the rights to 4 therapeutic classes of compounds in the treatment of oxidative stress, and has focused commercialization programs in clinical cardiovascular markers, including MPO (myeloperoxidase) and GPx (glutathione peroxidase), as well as the super potent antioxidant, Ergothioneine, that is planned to be introduced as an over-the-counter nutraceutical supplement. OXIS's customers include leading pharmaceutical companies such as Pfizer, Glaxo Smith Kline and Genzyme and universities such as Baylor College of Medicine, University of Minnesota, Virginia School of Technology, strategic business partners such as Minitube of America and Minitube Germany, distributors and government laboratories. OXIS has acquired a 51% interest in BioCheck, with the option to purchase the remaining 49%.

BioCheck is a provider of high quality enzyme immunoassay research services and products, and a leading provider of immunoassay kits for cardiac and tumor biomarkers, infectious diseases, thyroid function, steroids, and fertility hormones. BioCheck operates a 15,000 square-foot, U.S. Food and Drug Administration (FDA) certified cGMP, and ISO device-manufacturing facility in Foster City, California.

More information about OXIS, BioCheck and their products, services as well as current SEC filings may be obtained by visiting <http://www.oxisresearch.com> and <http://www.biocheckinc.com>.

The statements in this press release that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including, without limitation, statements regarding our expectations, objectives, anticipations, plans, hopes, beliefs, intentions or strategies regarding the future. Factors that could cause actual results to differ materially from the forward-looking statements include risks and uncertainties indicated in the company's filings with the Securities and Exchange Commission. It is important to note that actual outcomes could differ materially from those in such forward-looking statements.

Source: Oxis International Inc.